Idiopathic inflammatory myopathy

Summary

Idiopathic inflammatory myopathy (MONDO:0600023) is a disease and 18 clinical trials. Top therapeutic interventions include mycophenolate mofetil and zolacabtagene autoleucel. A subtype of myositis disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	idiopathic inflammatory myopathy
Mondo ID	MONDO:0600023
NCIT	C116796
SNOMED CT	702380008
UMLS	C0751356
MedGen	148290
GARD	0026301
Is cancer (heuristic)	no

Also known as: idiopathic myositis

Disease family

This is a subtype of myositis disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › myopathy › myositis disease › idiopathic inflammatory myopathy

Related subtypes (10): idiopathic granulomatous myositis, myositis ossificans, tendinitis, myositis fibrosa, inclusion body myositis, viral myositis, bacterial myositis, fungal myositis, infectious myositis, orbital myositis

Subtypes (2): acquired idiopathic inflammatory myopathy, familial idiopathic inflammatory myopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	7
Not specified	5
EARLY_PHASE1	4
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05129410	PHASE4	UNKNOWN	Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells
NCT06154252	PHASE2/PHASE3	RECRUITING	RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT05869955	PHASE1	RECRUITING	A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT06980597	PHASE1	RECRUITING	A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT07038447	PHASE1	ENROLLING_BY_INVITATION	A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07085104	PHASE1	RECRUITING	A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085676	PHASE1	RECRUITING	Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
NCT07229144	PHASE1	NOT_YET_RECRUITING	OM336 in Seropositive Autoimmune Diseases
NCT06913608	PHASE1	WITHDRAWN	A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
NCT06888960	EARLY_PHASE1	RECRUITING	Safety Study of CC312 in Autoimmune Disease Patients
NCT07072884	EARLY_PHASE1	NOT_YET_RECRUITING	GC012F in Patients With Autoimmune Diseases
NCT07086404	EARLY_PHASE1	RECRUITING	GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
NCT06462144	EARLY_PHASE1	TERMINATED	IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
NCT02468895	Not specified	ACTIVE_NOT_RECRUITING	MYOPROSP - a Prospective Cohort Study in Myositis
NCT06614270	Not specified	RECRUITING	Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NCT07150000	Not specified	RECRUITING	Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
NCT00971828	Not specified	COMPLETED	A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
NCT05027152	Not specified	COMPLETED	Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MYCOPHENOLATE MOFETIL	4	1
ZOLACABTAGENE AUTOLEUCEL	1	1